News | February 08, 2009

Modified Angioplasty Procedure May Reduce Heart Damage

February 9, 2009 - Emory University cardiologists are testing a modification of angioplasty known as postconditioning, designed to reduce permanent damage to the heart muscle after a heart attack.

The rush of blood back into the heart after a blood vessel is reopened during angioplasty can produce “reperfusion injury,” caused by biochemical changes in the heart muscle. The modified procedure inflates and deflates the balloon several times in a precisely controlled way, so that blood back flows into the heart gradually and thereby reduces the risk of reperfusion injury.

"This study could help refine a common, well-established procedure performed on thousands of patients every year," said principal investigator Habib Samady, M.D., associate professor of medicine (cardiology) at Emory University School of Medicine. "Without involving any additional drugs or devices, it may be possible to reduce damage to the heart muscle in a very straightforward way."

The Emory study — one of the first to test postconditioning in the U.S. — aims to determine whether postconditioning can benefit patients undergoing angioplasty and if so, to define how.

Post-conditioning has been tested in France, Israel, Denmark and Canada. In addition, a 2007 retrospective study of heart attack patients in Massachusetts who, without prior planning by doctors, required several balloon inflations showed that these patients had less damage to their hearts.

The Emory investigators will assess the degree of heart muscle damage in groups of patients treated with standard angioplasty versus those treated with a modified procedure using MRI and echocardiography.

The Emory study began in September 2008 and doctors have already treated several patients with the modified angioplasty procedure, with a total of 40 participants planned.

For more information: www.whsc.emory.edu

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init